EVALUATION OF PSYCHOMETRIC PROPERTIES OF EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 15 PALLIATIVE (EORTC QLQ-C15-PAL) IN MULTIPLE MYELOMA PATIENTS
(Abstract release date: 05/19/16)
EHA Library. Hu H. 06/09/16; 132988; E1439
Dr. Henry Hu
Contributions
Contributions
Abstract
Abstract: E1439
Type: Eposter Presentation
Background
The EORTC QLQ-C15-PAL was developed by shortening the QLQ-C30 from 30 to 15 items for easier administration to patients receiving palliative care. Its performance in measuring health-related quality of life (HRQoL) in relation to its parent version in patients with multiple myeloma (MM) has not been previously evaluated.
Aims
To assess the psychometric properties of the EORTC QLQ-C15-PAL in relation to the QLQ-C30 in patients with MM at different disease stages.
Methods
US patients with self-reported MM were recruited through an online patient-powered network, PatientsLikeMe. Upon completion of informed consent, study participants were asked to provide a brief MM treatment history and complete the EORTC QLC-C30. Domain scores for QLQ-C30 and QLQ-C15-PAL were calculated. Item-scale correlations, and floor and ceiling effects for all items on the QLQ-C30 were stratified by disease progression and palliative care status separately. To measure equivalent-form reliability, regression analysis was used to determine the proportion of variance (R-squared) using QLQ-C30 as the response variable and QLQ-C15-PAL as the explanatory variable for those domains shortened in the QLQ-C15-PAL. Intraclass correlation coefficients (ICCs) were calculated between the subscales shortened in QLQ-C15-PAL. The internal consistency of domains with 2 or more items was assessed using Cronbach a coefficients.
Results
A total of 199 patients completed the online survey, and 10 patients were excluded from the analysis because they had not received any MM treatment. Of the remaining 189 patients, the median age was 61 years (range, 37-82 years) and 57.6% were women. 51 patients (27.0%) received palliative care currently or previously and 65 patients (34.4%) switched treatment regimens at least once due to disease progression. With few exceptions, item-scale correlation, and floor and ceiling effects were in similar ranges for all items regardless of disease progression status or palliative care status. R-squared values ranged from 0.72 to 0.92 and ICCs varied from 0.87 to 0.96. Cronbach a coefficients for Physical Functioning, Emotional Functioning, and Fatigue were 0.64, 0.76, and 0.76, respectively.
Conclusion
The EORTC QLQ-C15-PAL appears to be a reasonable substitute to measure HRQoL in patients with MM at different disease stages.
Session topic: E-poster
Type: Eposter Presentation
Background
The EORTC QLQ-C15-PAL was developed by shortening the QLQ-C30 from 30 to 15 items for easier administration to patients receiving palliative care. Its performance in measuring health-related quality of life (HRQoL) in relation to its parent version in patients with multiple myeloma (MM) has not been previously evaluated.
Aims
To assess the psychometric properties of the EORTC QLQ-C15-PAL in relation to the QLQ-C30 in patients with MM at different disease stages.
Methods
US patients with self-reported MM were recruited through an online patient-powered network, PatientsLikeMe. Upon completion of informed consent, study participants were asked to provide a brief MM treatment history and complete the EORTC QLC-C30. Domain scores for QLQ-C30 and QLQ-C15-PAL were calculated. Item-scale correlations, and floor and ceiling effects for all items on the QLQ-C30 were stratified by disease progression and palliative care status separately. To measure equivalent-form reliability, regression analysis was used to determine the proportion of variance (R-squared) using QLQ-C30 as the response variable and QLQ-C15-PAL as the explanatory variable for those domains shortened in the QLQ-C15-PAL. Intraclass correlation coefficients (ICCs) were calculated between the subscales shortened in QLQ-C15-PAL. The internal consistency of domains with 2 or more items was assessed using Cronbach a coefficients.
Results
A total of 199 patients completed the online survey, and 10 patients were excluded from the analysis because they had not received any MM treatment. Of the remaining 189 patients, the median age was 61 years (range, 37-82 years) and 57.6% were women. 51 patients (27.0%) received palliative care currently or previously and 65 patients (34.4%) switched treatment regimens at least once due to disease progression. With few exceptions, item-scale correlation, and floor and ceiling effects were in similar ranges for all items regardless of disease progression status or palliative care status. R-squared values ranged from 0.72 to 0.92 and ICCs varied from 0.87 to 0.96. Cronbach a coefficients for Physical Functioning, Emotional Functioning, and Fatigue were 0.64, 0.76, and 0.76, respectively.
Conclusion
The EORTC QLQ-C15-PAL appears to be a reasonable substitute to measure HRQoL in patients with MM at different disease stages.
Session topic: E-poster
Abstract: E1439
Type: Eposter Presentation
Background
The EORTC QLQ-C15-PAL was developed by shortening the QLQ-C30 from 30 to 15 items for easier administration to patients receiving palliative care. Its performance in measuring health-related quality of life (HRQoL) in relation to its parent version in patients with multiple myeloma (MM) has not been previously evaluated.
Aims
To assess the psychometric properties of the EORTC QLQ-C15-PAL in relation to the QLQ-C30 in patients with MM at different disease stages.
Methods
US patients with self-reported MM were recruited through an online patient-powered network, PatientsLikeMe. Upon completion of informed consent, study participants were asked to provide a brief MM treatment history and complete the EORTC QLC-C30. Domain scores for QLQ-C30 and QLQ-C15-PAL were calculated. Item-scale correlations, and floor and ceiling effects for all items on the QLQ-C30 were stratified by disease progression and palliative care status separately. To measure equivalent-form reliability, regression analysis was used to determine the proportion of variance (R-squared) using QLQ-C30 as the response variable and QLQ-C15-PAL as the explanatory variable for those domains shortened in the QLQ-C15-PAL. Intraclass correlation coefficients (ICCs) were calculated between the subscales shortened in QLQ-C15-PAL. The internal consistency of domains with 2 or more items was assessed using Cronbach a coefficients.
Results
A total of 199 patients completed the online survey, and 10 patients were excluded from the analysis because they had not received any MM treatment. Of the remaining 189 patients, the median age was 61 years (range, 37-82 years) and 57.6% were women. 51 patients (27.0%) received palliative care currently or previously and 65 patients (34.4%) switched treatment regimens at least once due to disease progression. With few exceptions, item-scale correlation, and floor and ceiling effects were in similar ranges for all items regardless of disease progression status or palliative care status. R-squared values ranged from 0.72 to 0.92 and ICCs varied from 0.87 to 0.96. Cronbach a coefficients for Physical Functioning, Emotional Functioning, and Fatigue were 0.64, 0.76, and 0.76, respectively.
Conclusion
The EORTC QLQ-C15-PAL appears to be a reasonable substitute to measure HRQoL in patients with MM at different disease stages.
Session topic: E-poster
Type: Eposter Presentation
Background
The EORTC QLQ-C15-PAL was developed by shortening the QLQ-C30 from 30 to 15 items for easier administration to patients receiving palliative care. Its performance in measuring health-related quality of life (HRQoL) in relation to its parent version in patients with multiple myeloma (MM) has not been previously evaluated.
Aims
To assess the psychometric properties of the EORTC QLQ-C15-PAL in relation to the QLQ-C30 in patients with MM at different disease stages.
Methods
US patients with self-reported MM were recruited through an online patient-powered network, PatientsLikeMe. Upon completion of informed consent, study participants were asked to provide a brief MM treatment history and complete the EORTC QLC-C30. Domain scores for QLQ-C30 and QLQ-C15-PAL were calculated. Item-scale correlations, and floor and ceiling effects for all items on the QLQ-C30 were stratified by disease progression and palliative care status separately. To measure equivalent-form reliability, regression analysis was used to determine the proportion of variance (R-squared) using QLQ-C30 as the response variable and QLQ-C15-PAL as the explanatory variable for those domains shortened in the QLQ-C15-PAL. Intraclass correlation coefficients (ICCs) were calculated between the subscales shortened in QLQ-C15-PAL. The internal consistency of domains with 2 or more items was assessed using Cronbach a coefficients.
Results
A total of 199 patients completed the online survey, and 10 patients were excluded from the analysis because they had not received any MM treatment. Of the remaining 189 patients, the median age was 61 years (range, 37-82 years) and 57.6% were women. 51 patients (27.0%) received palliative care currently or previously and 65 patients (34.4%) switched treatment regimens at least once due to disease progression. With few exceptions, item-scale correlation, and floor and ceiling effects were in similar ranges for all items regardless of disease progression status or palliative care status. R-squared values ranged from 0.72 to 0.92 and ICCs varied from 0.87 to 0.96. Cronbach a coefficients for Physical Functioning, Emotional Functioning, and Fatigue were 0.64, 0.76, and 0.76, respectively.
Conclusion
The EORTC QLQ-C15-PAL appears to be a reasonable substitute to measure HRQoL in patients with MM at different disease stages.
Session topic: E-poster
{{ help_message }}
{{filter}}